Wellgistics launches Brenzavvy targeting $16B SGLT-2 inhibitor market

Wellgistics Health, Inc.

Brenzavvy launch targets 33M type II diabetics in US with out-of-pocket costs above cash price.
EinsteinRx AI platform alerts pharmacists to patients with Class 1A recommendation for SGLT-2 inhibitors.
Pharmacist-led provider education model aims to improve patient access and create revenue opportunity for pharmacists.
Wellgistics network includes 6,500+ independent pharmacies primarily in rural communities.
SGLT-2 inhibitor market reached $16.8B in 2024; US represents 40.8% of market.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.